A highly cited study examining the risks of heart disease in post-menopausal women with symptoms of polycystic ovary syndrome (PCOS) has been retracted by its authors because they could not replicate the results.
Here’s the retraction notice for the paper, which appeared in the Journal of Clinical Endocrinology & Metabolism: Continue reading Highly cited paper on women and heart disease retracted for failure to replicate
A Canadian research team has retracted a meeting abstract “published in error” from a supplement by Allergy, Asthma & Clinical Immunology, as it had previously been published in another journal.
The December 2014 abstract, “A post-hoc qualitative analysis of real time heads-up pollen counting versus traditional microscopy counting in the environmental exposure unit (EEU),” describes a custom digital imaging method for counting pollen in real-time. The abstract was published ten months earlier, in February 2014, under the same title in the Journal of Allergy and Clinical Immunology.
Here is the full retraction note:
The Journal of Bone and Joint Surgery has retracted a 2012 paper because of ethical violations, initially flagged by the journal in 2013.
The study, which examined the use of autologous cell therapy in treating Achilles tendinosis, claimed in its abstract to have “conducted a randomized, double-blind study on forty Achilles tendons in thirty-two patients.” Apparently, though, it wasn’t actually a clinical trial but was somehow, according to the retraction notice, “misclassified” as such “in error.”
The problem was originally flagged by the UK’s Medicines and Healthcare products Regulatory Agency, which wrote the journal to tell them that it hadn’t granted ethical approval for the study, as we reported in 2013. At the time, there was a question about whether the lead author had retained records of the results, which is addressed in the retraction notice, signed by editor-in-chief Marc F. Swiontkowski and editor-in-Chief Emeritus Vernon T. Tolo: Continue reading Clinical trial of Achilles tendon therapy retracted for not actually being a clinical trial
Cancer biologist Rakesh Kumar has chalked up another retraction, this time for “identical,” “duplicated,” and “replicated” figures and images.
It comes on the heels of a flurry of motions in Kumar’s $8 million lawsuit against his employer, George Washington University, for breach of contract and emotional distress because it removed him as department chair last year and placed his research on hold. Kumar remains employed by the university.
The retracted paper, published in Development in 2004, “Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis,” analyzed the role of a protein, MTA1, in mammary gland development and cancer. It was published while Kumar was at M.D. Anderson in Houston, and has been cited 81 times, according to Thomson Scientific’s Web of Knowledge.
By our count, Kumar now has three retractions and five corrections. Numerous anonymous comments on Kumar’s papers have been posted on PubPeer, many of them critiquing images. Here’s the complete notice from Development: Continue reading Third retraction for GWU biologist as university seeks to dismiss his $8 million lawsuit
The authors of a paper on dengue virus vaccine design published last year in PNAS are retracting it after discovering that their experimental dengue virus was contaminated.
Although they are confident that the strategy is sound, the authors write in their commendably detailed retraction notice that the “inadvertent error” rendered the results “uninterpretable.”
Here’s the retraction notice: Continue reading PNAS paper on dengue virus pulled due to contamination
Following an investigation into research misconduct, the Journal of Clinical Investigation has retracted a cancer genetics paper from a laboratory at the National Institutes of Health due to “data falsification and fabrication” of four figures and a table in the paper.
The paper, “FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer,” describes an overexpressed gene in mouse prostate cancers that appears to suppress immune system cells.
The journal retracted the paper following an investigation into author Stephanie K. Watkins, then a postdoctoral fellow at the National Cancer Institute. According to a NIH press release released about the study in March 2011, the work “has led to the submission of a patent application by the NIH on behalf of Hurwitz and Watkins to target FOXO3 as a way to boost immune responses in cancer and to silence excessive immune responses in autoimmune diseases.” We found an NIH record of the patent application, but no record of an approved patent at the United States Patent and Trademark Office under either Hurwitz or Watkins’ names.
The paper has been cited 62 times, according to Thomson Scientific’s Web of Knowledge. Here’s the full notice: Continue reading NIH cancer paper retracted for faked data
The suit, originally filed in February in the U.S. District Court of Southern Ohio by Mitch Potterf, owner of a Columbus, Ohio CrossFit, alleges that a 2013 paper by OSU’s Steven Devor and colleagues falsely reported that nine subjects had dropped out of the study because of “overuse or injury.” The study, we should note, concluded that CrossFit is a useful form of exercise. It has been cited twice, according to Thomson Scientific’s Web of Knowledge.
As John Thomas, an attorney who handles False Claims Act cases, explained in a Retraction Watch guest post in March: Continue reading CrossFit gym owner sues Ohio State, says fraudulent data led to $273 million in NIH grants
The author of a 2006 review article published in Abdominal Imaging has retracted it because it hews too closely to previously published articles.
The review described the latest imaging techniques used in cancer, focusing on genitourinary conditions.
Here’s the full text of the retraction notice for “New Horizons in Genitourinary Oncologic Imaging”:
Continue reading Highly cited cancer researcher pulls review for “similar text and illustrations”
The British Journal of Sports Medicine has “temporarily removed” an editorial arguing that physical activity alone will not cure the obesity epidemic, following an expression of concern.
In its place stands the following message:
This paper has been temporarily removed following an expression of concern.
First author Assem Malhotra, based at the Department of Cardiology, Frimley Park Hospital and Consultant Clinical Associate to the Academy of Medical Royal Colleges, told us the paper was pulled due to a “technical issue,” and an “official explanation” would be forthcoming.
Indeed, just this morning, we received a statement from Fiona Godlee, editor of the British Medical Journal, which publishes the British Journal of Sports Medicine:
The Egyptian Journal of Anaesthesia is retracting a 2014 paper by a pair of researchers at Cairo University who appear to have tinkered with their protocol after having received ethics approval.
The paper, titled “Can Sugammadex improve the reversal profile of Atracurium under Sevoflurane anesthesia?” was written by Heba Ismail Ahmed Nagy and Hany Wafik Elkadi, both in the department of anesthesiology.
Sugammadex, or Bridion, is given to rapidly reverse the effects of drugs that keep patients motionless during surgery. It is available throughout the world but not, as it happens, in the United States, where the Food and Drug Administration has refused to approve the agent because of fears that it might provoke severe allergic-like reactions.
According to the retraction notice:
Continue reading Drug study pulled after researchers admit altering trial protocol